(Q34734502)

4 August 2017

1 reference

title

Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer (English)

1 reference

4 August 2017

Tejada-Berges T

1

1 reference

4 August 2017

Granai CO

series ordinal

2

1 reference

4 August 2017

Gordinier M

series ordinal

3

1 reference

4 August 2017

Gajewski W

series ordinal

4

1 reference

4 August 2017

language of work or name

1 reference

1 April 2002

1 reference

Expert Review of Anticancer Therapy

4 August 2017

published in

1 reference

4 August 2017

volume

2

1 reference

4 August 2017

issue

2

1 reference

4 August 2017

page(s)

143-150

1 reference

Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.143

Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.143

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.143

Topotecan in platinum- and paclitaxel-resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.143

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.143

Impact of doxorubicin on survival in advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.143

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.143

Phase II study of liposomal doxorubicin in advanced gynecologic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.143

The clinical utility of liposomal doxorubicin in recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.143

Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.143

Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.143

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.143

Doxorubicin in sterically stabilized liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.143

21 January 2018

Identifiers

DOI

10.1586/14737140.2.2.143

1 reference

4 August 2017

1 reference